肺癌患者血清中IL-33表达水平与骨转移的相关性研究

Correlation between serum IL-33 expression and bone metastasis in patients with lung cancer

目的 探讨肺癌患者血清中IL-33表达水平与骨转移的相关性。方法 纳入本院39例肺癌患者(未转移组)、69例肺癌骨转移患者(骨转移组)及35例健康者(对照组)作为研究对象。检测所有研究对象血清中IL-33的表达水平,通过logistic回归分析探讨肺癌骨转移患者血清中IL-33表达水平的影响因素,IL-33在鉴别对照组和骨转移组及未转移组和骨转移组间的临床效能采用ROC曲线分析。对69例肺癌骨转移患者至少随访18月,采用K-M曲线分析IL-33高表达对肺癌骨转移患者预后的影响。结果 对照组、未转移组、骨转移组患者血清中IL-33表达水平分别为(27.58±8.13)ng/ml、(54.61±10.72)ng/ml和(75.59±12.44)ng/ml, 3组血清中IL-33表达水平相比差异有统计学意义(F=222.27,P<0.001),与对照组和未转移组相比,骨转移组血清中IL-33表达水平显著升高(P<0.001)。临床分期(OR=6.432)、骨转移数目(OR=35.891)、合并其他脏器转移(OR=4.445)均是肺癌骨转移患者血清中IL-33表达水平升高的独立危险因素。血清IL-33表达水平在鉴别诊断对照组和骨转移组及未转移组和骨转移组的AUC分别为0.976和0.815。生存分析结果显示,IL-33高表达的肺癌骨转移患者的临床预后较差(OR=3.121,95%CI:1.211~6.551,P<0.05)。结论 肺癌骨转移患者血清中IL-33表达水平显著升高,且IL-33可作为肺癌骨转移的一个血清学标志物,IL-33高表达与肺癌骨转移患者的不良预后有关。

Objective This paper aims to investigate the correlation between serum IL-33 level and bone metastasis in patients with lung cancer. Methods A total of 39 patients with lung cancer(non-metastasis group), 69 bone metastasis in patients with lung cancer(bone metastasis group) and 35 healthy people(control group) in our hospital were enrolled. The serum levels of IL-33 in all individuals were detected, and the influencing factors of the levels of IL-33 in patients with bone metastases from lung cancer were investigated by logistic regression analysis. The clinical efficacy of IL-33 in differentiating the control group and the bone metastasis group, and the non-metastasis group and bone metastasis group were analyzed by ROC curve. A total of 69 patients with bone metastases from lung cancer were followed up for at least 18 months. The K-M curve was used to analyze the effect of high IL-33 expression on the prognosis of patients with bone metastases from lung cancer. Results The serum levels of IL-33 in control group, non-metastasis group and bone metastasis group were(27.58±8.13) ng/ml,(54.61±10.72) ng/ml and(75.59±12.44) ng/ml, respectively. There was statistical significance on the differences in the serum levels of IL-33 among the three groups(F=222.27, P<0.001). Compared with the control group and the non-metastatic group, the serum level of IL-33 in bone metastasis group was significantly increased(P<0.001). The clinical stage(OR=6.432), the number of bone metastases(OR=35.891), and other organ metastases(OR=4.445) were all independent risk factors for elevated serum IL-33 levels in patients with bone metastases from lung cancer. The AUC of serum IL-33 expression in differentiate control group and bone metastasis group, and non-metastasis group and bone metastasis group were 0.976 and 0.815, respectively. The survival analysis showed that the high expression of IL-33 was correlated with poor prognosis(OR=3.121, 95%CI: 1.211-6.551, P<0.05). Conclusion The serum level of IL-33 in patients with bone metastases from lung cancer is significantly increased. IL-33 is a biological marker for the differential diagnosis of bone metastases of lung cancer. High expression of IL-33 is associated with poor prognosis of patients with bone metastases from lung cancer.